AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06019780 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Following exercises will be performed without application of pneumatic cuff~1. Side lying external rotation~2. Prone horizontal abduction~3. Standing scaption Conventional treatment will include: Hot pack 5 mins Maitland grade 3 and 4 mobilization: inferior glide (10reps x3sets), posterior glide (10reps x 3sets), anterior glide (10 reps x 3sets) Home plan: wand exercise, pendulum exercise, wall walking exercise (10reps x 2sets each)
Study NCT06500286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marciane
Description: Group A caudal block 0.25% bupivacaine was administered at a dose of 0.2 ml/k
Study NCT06500286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine
Description: Dorsal penil block 0.25% bupivacaine was administered at a dose of 0.2 ml/k
Study NCT04291521 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Description: Administering ketamine as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
Study NCT04291521 — intervention group
Intervention type: DRUG
Intervention: Etomidate
Description: Administering etomidate as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
Study NCT04291521 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Administering propofol as an induction medication for intubating adult trauma patients within 24 hours of hospital admission.
Study NCT06681779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Physical pain stimulation, as used in traditional standard care, will be used to score the GCS exam, and the device results will be compared to this SOC exam.
Study NCT06002178 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neck ultrasound
Description: A neck ultrasound will be performed in order to map superficial arteries and veins of the neck
Study NCT06115746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iDECIDE
Description: iDECIDE is a 4-session drug education and diversion program that addresses topics such as the neurobiology and addiction, adolescent brain development, industry tactics, motives for using substances, risk and protective factors, identifying triggers, healthy alternatives, core values, and long-term goal setting. These topics are taught via facilitated discussions, videos, worksheets, and handouts. The iDECIDE drug curriculum will be delivered weekly for 4 weeks via videoconference or in-person visits. Each session typically takes 60-75 minutes. For this study, facilitators are members of study staff.
Study NCT06680531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139 tablets
Description: YZJ-1139 tablets are administered orally single dose
Study NCT06680531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram oxalate tablets
Description: •oral tablet, QD
Study NCT06680531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram oxalate tablets
Description: •oral tablet, QD
Study NCT06680531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139 simulated tablets
Description: oral tablet, QD
Study NCT06680531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YZJ-1139 simulated tablets
Description: oral tablet, QD
Study NCT04750668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory Balance Training
Description: Multisensory Balance training includes 30 minutes per day, 5 days a week for 4 weeks, using visual, proprioceptive, and vestibular manipulations. The exercises involved movements of the eye, head, and body to stimulate the vestibular system, postural control exercises in different positions (feet together, tandem stance, and one leg stance), use of a soft surface to reduce the proprioceptive inputs, and exercises with closed eyes to deprive them of visual cues.
Study NCT06680349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-CD20 antibodies
Description: comparing anti-CD20 (lymphoma protcol, RTX 375 mg/m2 every 4 weeks ) alone Vs. Intensive B-cell depletion therapy (IBCDT) which is based on the combination of RTX (given at the dose of 375 mg/m2 every 4 weeks followed by 2 additional doses after 1 and 2 months), cyclophosphamide (two pulses of 10 mg/kg, corrected according to renal function, on days 4 and 17) and methylprednisolone (three bolus doses of 15 mg/kg) followed by oral prednisone (starting dose 50 mg tapered until complete discontinuation in 4 months).
Study NCT06680349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD20 antibodies
Description: comparing anti-CD20 (lymphoma protcol, RTX 375 mg/m2 every 4 weeks ) alone Vs. Intensive B-cell depletion therapy (IBCDT) which is based on the combination of RTX (given at the dose of 375 mg/m2 every 4 weeks followed by 2 additional doses after 1 and 2 months), cyclophosphamide (two pulses of 10 mg/kg, corrected according to renal function, on days 4 and 17) and methylprednisolone (three bolus doses of 15 mg/kg) followed by oral prednisone (starting dose 50 mg tapered until complete discontinuation in 4 months).
Study NCT06623682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive behavioural therapy
Description: Transdiagnostic cognitive behavioural therapy for both depression and anxiety that including modules from (1) Mindfulness-based intervention, (2) Rumination-focused cognitive behavioural therapy, and also including modules for insomnia and from Mindwork (Internet-based cognitive behavioural therapy).
Study NCT05169281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Disposal Packet
Description: The disposal packet (DisposeRx Inc.) contains a powder that sequesters unused opioids in a polymer gel. The kits reached patients four days following their surgery based on prior data to leverage availability bias, or a tendency to think or act on things that are most present in one's mind, and provided patients with a disposal technique when they were likely to be finished with their opioids. The process of mailing the disposal packet is simple, low cost (\~$1.50/ mailed packet) and scalable.
Study NCT06680882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular Acupoint Stimulation +prucapride
Description: The study group, comprising 30 individuals, received a combination therapy of non-invasive auricular acupoint stimulation and prucapride
Study NCT06680882 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: prucapride
Description: was administered prucapride as a monotherapy
Study NCT05092971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock or startle device
Description: Shock and startle devices were used as aversive stimulus (shock and startle)
Study NCT06199687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Virtual Reality
Description: Use of Virtual Reality after After Thyroid-Parathyroid Surgery
Study NCT03321760 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiation Therapy (SABR)
Description: SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.
Study NCT06556641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR33 Injection
Description: Administered as once daily subcutaneous dose
Study NCT06556641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR101 Injection
Description: Administered as once daily subcutaneous dose
Study NCT06556641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as once daily subcutaneous dose
Study NCT06556641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Administered as once daily subcutaneous dose
Study NCT06633796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMADEO
Description: 304 / 5.000 The rehabilitation treatment includes 10 sessions of combined treatment of paraffin therapy, functional occupational therapy and polyarticular mobilization of the fingers with a robotic arm (Amadeo). The sessions will be scheduled 2 times a week for 5 consecutive weeks.
Study NCT06633796 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of care
Description: The rehabilitation treatment includes 10 sessions of combined treatment of paraffin therapy and occupational therapy for functional purposes. The sessions will be scheduled 2 times a week for 5 consecutive weeks.
Study NCT05324722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pragmatic posterior capsular stretch
Description: pragmatic posterior stretch is used to increase the length of the posterior capsule
Study NCT05324722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cross body stretch
Description: crossbody stretch performed by an individual
Study NCT06355557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AI enabled ultrasound system for self-directed learning
Description: use of the AI enabled ultrasound system for self-directed learning
Study NCT06355557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulator for self-directed learning
Description: use of the simulator for self-directed learning
Study NCT06355557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional with human instructors
Description: Medical students who are randomised to this arm
Study NCT06675669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflective thinking method
Description: It will be applied to students in the initiative group for 1 hour per week for 7 weeks.
Study NCT06621277 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06621277 — intervention group
Intervention type: OTHER
Intervention: Tailored counseling programs (Phase 2)
Description: Optimized care services and tailored counseling programs for young patients with GI tumors at the Heidelberg University Hospital (Phase 2)
Study NCT05509751 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GAM, exercise, health education
Description: geriatric assessment, exercise and health education
Study NCT05509751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online chair-based exercise combined with health education
Description: online chair-based exercise and health education for 12 weeks
Study NCT05734495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor, tablet taken orally.
Study NCT05186818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg)
Description: CK-3773274 tablets administered orally
Study NCT05186818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match CK-3773274
Description: Placebo administered orally
Study NCT04659031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC008
Description: ABC008
Study NCT06629961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abutment placement
Description: Placement of a subcrestal implant at more than 35 N and placement of a trans-epithelial abutment at 30 N
Study NCT06629961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ti-base placement
Description: Placement of a subcrestal implant at more than 35 N and placement of a Tibase placement at 30 N
Study NCT04809805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2666605
Description: One oral solution strength of BAY2666605 will be used. Two different tablet strengths of BAY2666605 will be available.
Study NCT05715762 — intervention group
Intervention type: BEHAVIORAL
Intervention: prone postion
Description: ventilation at prone positioning
Study NCT05715762 — intervention group
Intervention type: DRUG
Intervention: NO inhalation
Description: NO inhalation at 20 ppm
Study NCT05046730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ileostomy Reversal using Self Forming Magnets (SFM)
Description: The magnets will be manually deployed into the small intestine during open surgery following creation of a mini or full laparotomy as clinically indicated. Once the desired segment of small bowel is resected, the magnet is inserted through the open ends of each bowel section. Once proper magnet position is confirmed and the bowel ends are approximated, the magnets couple to form the anastomosis.
Study NCT05046730 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ileostomy Reversal using Self Forming Magnets (SFM)
Description: The magnets will be manually deployed into the small intestine during open surgery following creation of a mini or full laparotomy as clinically indicated. Once the desired segment of small bowel is resected, the magnet is inserted through the open ends of each bowel section. Once proper magnet position is confirmed and the bowel ends are approximated, the magnets couple to form the anastomosis.
Study NCT05385978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APHD-012
Description: Distal jejunal-release dextrose beads (Aphaia technology, AT)
Study NCT05385978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: APHD-012P
Description: Distal jejunal-release placebo beads
Study NCT05734495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor, tablet taken orally.
Study NCT05259553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Peripheral blood sampling will be performed at different time points of the study, for a total volume of 20-40 mL:~* Sampling before MM treatment,~* Sampling during MM treatment (at 3 months post-initiation if no autograft or before autograft),~* Only for Patients treated with Apixaban or Eliquis®, 2 additional samplings during MM treatment for pharmacokinetics analysis.
Study NCT06000722 — intervention group
Intervention type: OTHER
Intervention: eDelphi method
Description: This is a Delphi technique-based study using a purposive sample of convenience. Consensus development methods will be used to generate clinical guidelines, endorsed by key clinical groups, on the use of SGLT2i's in patients with diabetic foot ulcer disease, including acknowledgement of specific scenarios or patient characteristics that may influence these guidelines.
Study NCT05754190 — intervention group
Intervention type: DEVICE
Intervention: SOMA pain manager smartphone application
Description: SOMA is a smartphone application developed for acute and chronic pain patients to track daily mood and pain symptoms and overall activity.
Study NCT04367116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Spinal cord stimulation is a treatment that implants a electrode in posterior epidural space of patient's spinal canal to send mild electric current to stimulate conducting bundle of the posterior column of the spinal cord and posterior horn sensory neurons.
Study NCT06524180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: a mobile app and telemedicine platform to confirm good blood pressure control and may save doctor face-to-face consultation
Study NCT06524180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will be followed up as usual by face-to-face consultation with the doctors
Study NCT05459753 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: (18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET
Description: Participants will receive an injection of 8 mCi \[18F\]FEOBV PET tracer and undergo a CT of the head.
Study NCT05459753 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dihydrotetrabenazine (DTBZ) PET
Description: Participants will receive an injection of 15 mCi \[11C\]DTBZ PET tracer and undergo a CT of the head.
Study NCT05515224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5-Cog Paradigm (5-Cog battery coupled with clinical decision tool)
Description: A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. If cognitive concerns are endorsed the 5-Cog battery will be conducted. The 5-Cog battery includes the Picture Memory Impairment Screen, Motoric Cognitive Risk Syndrome diagnosis, and Symbol Match. The simple, \<5-minute cognitive assessment will reliably identify older persons with cognitive impairment in primary care settings, and flag them for further evaluation.
Study NCT05515224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: A cognitive concern screening will be conducted with patients aged 65 and older prior to their appointment with their primary care physician. The results will be provided to primary care physicians.
Study NCT05845580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red yeast rice extract initial therapy followed later on by statin therapy
Description: Patients will be offered red yeast rice extract to achieve a target LDL-cholesterol level of \<2.6 mmol/L, as recommended by the 2019 ESC/EAS guidelines. If a patient's LDL-cholesterol level remains above the target during follow-up, they will be informed that the natural alternative was ineffective, and they will be prescribed atorvastatin.
Study NCT05845580 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Statin therapy
Description: Patients will be provided reassurance through a short, semi-structured discussion on the excellent safety profile of statins, similar to a typical interaction between a clinician and patient. They will then be prescribed atorvastatin.
Study NCT06018519 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical endpoints
Description: 1. Number of epileptic seizures~2. Change in antiepileptic treatment (increase or decrease)~3. Visual analogical scale on a target symptom defined with the parents,~4. CGI,~5. Actimetry data over 24 hours,~6. Podometry data over 24 hours,~7. 6 minutes' walk test,~8. Clinical examination~9. Feasibility of performing an MRI without any anesthesia on a mock scanner
Study NCT06018519 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parental questionnaires
Description: 10- Adaptive assessment with Vineland Adaptive Behavior scale II,~11- Mac Arthur questionnaire regarding language,~12- Pervasive Development Disorder in Mentally Retarded persons Scale (PDD-MRS),~13- Dunn sensory profile,~14- Aberrant Behavior Checklist,~15- Nisonger Child Behavior Rating form,~16- Social Responsiveness Scale 2,~17- Scales assessing the impact on primary caregiver (CBI-M/ Beach Center Family QOL)
Study NCT06018519 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Quality of life scale
Description: 18- Quality of life scale (PedsQL 4.0 for children or San Martin scale if the patient is older than 18)
Study NCT05493332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC(FOLFOX)
Description: After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of chemotherapy drugs.
Study NCT05493332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 IVdrip from hour 0 to 2 on D1，Q3W
Study NCT05493332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400mg/m2 IVdrip , from hour 0 to 2 on D1 to D2，Q3W
Study NCT05493332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 400mg/m2 , bolus at hour 3 ; and 600mg/m2 IVdrip over 46 hours on D1 to D2，Q3W
Study NCT05493332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg IVdrip，D3, Q3W
Study NCT05493332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: 0.1g. P.O, BID, continuously
Study NCT04835519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: chimeric antigen receptor T cell
Description: Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 5 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m\^2( body surface area) and cyclophosphamide 250 mg/m\^2( body surface area) for 3 days. Then this study will be using the Bayesian optimal interval phase I/II (Boin12) trial design. The protocol preset 2 dose levels: Dose 1 (DL-1) was 5×10\^5 (±20%) CAR T cells/kg, and dose 2 (DL-2) was 1×10\^6 (±20%) CAR T cells/kg. If the above dose cannot be met, subjects can still enter the study upon investigator consideration but require documentation of dosing. The lowest dose is 1×10\^5 CAR T cells/kg (±20%), and the highest dose is 1×10\^6 CAR T cells/kg (±20%). If the dose is out of the range mentioned above, entry into the trial will not be considered.
Study NCT05959733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bridging Reconstruction using BioBrace
Description: Patients in the reconstruction group will undergo maximal repair with interposition bridging using BioBrace. This technique will follow a previously described technique by the principal investigator with differences allocated to the graft, it's preparation and insertion. The bursa will be debrided, and rotator cuff edged will be shaved down to stable tissue. BioBrace is bioinductive scaffold composed of highly porous type I collagen and bio-resorbable poly (L-lactide) (PLLA) microfilaments, and will be used as the graft in this trial.
Study NCT05959733 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repair
Description: Patients in the maximal repair group will undergo a SCOI-row rotator cuff repair with adequate tension as described previously, with recreation of the rotator cable. Briefly, the SCOI-row rotator cuff repair uses one triple loaded suture anchor for each 1.2cm of torn tendon. This technique has been completed in a previous randomized controlled trial.